Literature DB >> 32543938

Palliative care for advanced gastric cancer.

Kazuto Harada1,2, Meina Zhao1, Namita Shanbhag1, Hideo Baba2, Jaffer A Ajani1.   

Abstract

INTRODUCTION: Proactive palliative care can effectively relieve symptoms early and effectively as well as improve the quality of life of patients with gastric adenocarcinoma (GAC). AREAS COVERED: The review summarizes palliative care for GAC. GAC caused specific symptoms, such as malignant gastric outlet obstruction (GOO), bleeding, weight loss, and/or ascites, therefore, these symptoms must be addressed specifically. EXPERT OPINION: Palliative care should start early to control general symptoms, thus may improve the patient's condition to make the patient eligible for anti-cancer treatment. As some stage IV GAC patients can now live longer, palliative interventions become more important. A multimodality interdisciplinary approach is strongly encouraged.

Entities:  

Keywords:  Gastric adenocarcinoma; malignant gastric outlet obstruction; palliative care; palliative gastrectomy; palliative radiotherapy

Mesh：

Year:  2020        PMID： 32543938      PMCID： PMC7415645          DOI： 10.1080/14737140.2020.1781620

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


  76 in total

1.  The role of palliative radiation therapy in symptomatic locally advanced gastric cancer.

Authors:  Jeremy Tey; Michael F Back; Thomas P Shakespeare; Rahul K Mukherjee; Jiade J Lu; Khai Mun Lee; Lea Choung Wong; Cheng Nang Leong; Ming Zhu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-21       Impact factor: 7.038

2.  Stomach-partitioning gastrojejunostomy for unresectable gastric carcinoma.

Authors:  M Kaminishi; H Yamaguchi; N Shimizu; S Nomura; A Yoshikawa; M Hashimoto; S Sakai; T Oohara
Journal:  Arch Surg       Date:  1997-02

Review 3.  Treatment of gastric outlet obstruction that results from unresectable gastric cancer: Current evidence.

Authors:  Yasuhiro Miyazaki; Shuji Takiguchi; Tsuyoshi Takahashi; Yukinori Kurokawa; Tomoki Makino; Makoto Yamasaki; Kiyokazu Nakajima; Masaki Mori; Yuichiro Doki
Journal:  World J Gastrointest Endosc       Date:  2016-02-10

Review 4.  Gastric adenocarcinoma.

Authors:  Jaffer A Ajani; Jeeyun Lee; Takeshi Sano; Yelena Y Janjigian; Daiming Fan; Shumei Song
Journal:  Nat Rev Dis Primers       Date:  2017-06-01       Impact factor: 52.329

5.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Authors:  Charles S Fuchs; Jiri Tomasek; Cho Jae Yong; Filip Dumitru; Rodolfo Passalacqua; Chanchal Goswami; Howard Safran; Lucas Vieira Dos Santos; Giuseppe Aprile; David R Ferry; Bohuslav Melichar; Mustapha Tehfe; Eldar Topuzov; John Raymond Zalcberg; Ian Chau; William Campbell; Choondal Sivanandan; Joanna Pikiel; Minori Koshiji; Yanzhi Hsu; Astra M Liepa; Ling Gao; Jonathan D Schwartz; Josep Tabernero
Journal:  Lancet       Date:  2013-10-03       Impact factor: 79.321

6.  Gastrojejunostomy versus stent placement in patients with malignant gastric outlet obstruction: a comparison in 95 patients.

Authors:  S M Jeurnink; E W Steyerberg; G van 't Hof; C H J van Eijck; E J Kuipers; P D Siersema
Journal:  J Surg Oncol       Date:  2007-10-01       Impact factor: 3.454

7.  Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.

Authors:  Kazumasa Fujitani; Han-Kwang Yang; Junki Mizusawa; Young-Woo Kim; Masanori Terashima; Sang-Uk Han; Yoshiaki Iwasaki; Woo Jin Hyung; Akinori Takagane; Do Joong Park; Takaki Yoshikawa; Seokyung Hahn; Kenichi Nakamura; Cho Hyun Park; Yukinori Kurokawa; Yung-Jue Bang; Byung Joo Park; Mitsuru Sasako; Toshimasa Tsujinaka
Journal:  Lancet Oncol       Date:  2016-01-26       Impact factor: 41.316

8.  Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry.

Authors:  Atsushi Nashimoto; Kohei Akazawa; Yoh Isobe; Isao Miyashiro; Hitoshi Katai; Yasuhiro Kodera; Shunichi Tsujitani; Yasuyuki Seto; Hiroshi Furukawa; Ichiro Oda; Hiroyuki Ono; Satoshi Tanabe; Michio Kaminishi
Journal:  Gastric Cancer       Date:  2012-06-23       Impact factor: 7.370

9.  Covered metallic stents with an anti-migration design vs. uncovered stents for the palliation of malignant gastric outlet obstruction: a multicenter, randomized trial.

Authors:  Hyuk Lee; Byung-Hoon Min; Jeong Hoon Lee; Cheol Min Shin; Younjoo Kim; Hyunsoo Chung; Sang Hyub Lee
Journal:  Am J Gastroenterol       Date:  2015-09-15       Impact factor: 10.864

10.  Stenting in Palliation of Unresectable Esophageal Cancer.

Authors:  Janusz R Włodarczyk; Jarosław Kużdżał
Journal:  World J Surg       Date:  2018-12       Impact factor: 3.352
View more
  3 in total

1.  Development and internal validation of laboratory prognostic score to predict 14-day mortality in terminally ill patients with gastrointestinal malignancy.

Authors:  Hidemasa Nagai; Natsuko Kawai; Norihiro Yuasa
Journal:  Support Care Cancer       Date:  2022-01-27       Impact factor: 3.603

2.  Safety Analysis of Apatinib Combined with Chemotherapy in the Treatment of Advanced Gastric Carcinoma: A Randomised Controlled Trial.

Authors:  Min Yuan; Zhaohui Wang; Yibo Zhang; Liying Chen; Yuting Liu; Cui Cui; Bo Sun
Journal:  J Oncol       Date:  2021-08-09       Impact factor: 4.375

3.  Environmental and Socioeconomic Factors for Gastric Cancer in 14 Counties of the Huai River Basin from 2014 to 2018.

Authors:  Yongqing Lin; Bixiong Ye; Qin Wang; Shaoxia Dong
Journal:  Int J Environ Res Public Health       Date:  2022-02-15       Impact factor: 3.390
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.